Retraction Note: J Ovarian Res 13, 113 (2020)
https://doi.org/10.1186/s13048-020-00719-3
The Editors-in-Chief have retracted this article [1]. Concerns were raised with Figures 2 and 3, specifically:
-
Figure 2E: the panels for Group-2 and Group-3 appear to partially overlap.
-
Figure 2E: the panels for nab-P and AP appear to partially overlap.
-
Figure 3E: the panels for Bax/Group-1 and Bax/Group-3 appear to partially overlap.
-
Figure 3E: the panels for Bax/Group-2 and bcl-2/Control group appear to partially overlap.
-
Figure 3E: the panel for CD31/Group-1 appears to partially overlap with the panels for CD31/Group-3 and MMP-2/Group-2.
-
Figure 3E: the panel for CD31/Group-3 appears to partially overlap with the panels for MMP-2/Group-1 and MMP-2/Group-2.
-
Figure 3E: the panel for CD31/Group-3 appears to partially overlap with the panel for MMP-2/Group-1.
-
Figure 3E the panels for MMP-2/Group-1 and MMP-2/Group-2 appear to partially overlap.
The Editors-in-Chief have therefore concluded that the data reported in this article are unreliable. The authors have not responded to any correspondence regarding this retraction
Reference
Zhao H, Li R, Wang X, et al. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer. J Ovarian Res. 2020;13:113 https://doi.org/10.1186/s13048-020-00719-3.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhao, H., Li, R., Wang, X. et al. Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer. J Ovarian Res 14, 37 (2021). https://doi.org/10.1186/s13048-021-00785-1
Published:
DOI: https://doi.org/10.1186/s13048-021-00785-1